Review Papers Claim by Claim

Concise synthesis (evidence-linked)

• Primary experimental finding: elevated extracellular lactate prevented the normal increase in RBC-derived extracellular ATP in response to acute low PO2; DCA restored the ATP release response to low PO2 despite intracellular ATP remaining reduced relative to control (Rozier et al. primary data).
• Interpretation the authors favor: lactate inhibits glycolytic ATP supply to a localized/releasable ATP pool (not fully reflected by bulk intracellular ATP), and DCA restores the releasable pool's function (paper discussion and inference) (Rozier mechanistic interpretation).
• Clinical context: authors motivated study by associations of hyperlactataemia with poor outcomes in sepsis/malaria and prior observations that malaria-infected RBCs fail to release ATP on low PO2; they suggest lactate-mediated impairment of RBC vascular signaling could contribute to tissue hypoperfusion (paper introduction) (Rozier clinical context).

Critical appraisal — strengths, limitations, and blindspots

• Strengths: clear, simple in vitro design; direct measurements of extracellular and intracellular ATP; inclusion of wash steps and controlled gas baths to isolate PO2 effect; rescue experiment with clinically-scaled DCA dose strengthens causal interpretation that lactate is involved (Rozier methods and strengths).
• Limitations / cautionary points:
  1. Species/model: experiments used rabbit RBCs ex vivo; human RBC responses (and pathological milieu with other circulating factors, pH shifts, inflammatory mediators) may differ — extrapolation to human sepsis/malaria is indirect (Rozier limitation: species/model).
  2. High lactate concentration: the experimental lactate (≈21 mmol·L⁻¹) sits at the high end of clinical observations (authors acknowledge); dose–response behavior at lower clinically relevant lactate (2–10 mmol·L⁻¹) wasn't characterized, leaving uncertainty about physiological relevance in many patients (Rozier limitation: lactate dose).
  3. Mechanistic gap: while supportive of a localized/releasable ATP pool concept, the paper does not directly measure membrane-associated glycolytic enzyme activity, lactate/pyruvate ratios in RBC microdomains, or transport via monocarboxylate transporters; alternative mechanisms (lactate affecting PO2 sensing, G-protein signaling, ATP transport channels) are acknowledged but not experimentally separated (Rozier acknowledged blindspots).
  4. Temporal limitations: DCA was applied for 1 h after lactate and restored ATP release while intracellular ATP remained low; kinetics and stability of the rescue (how long restored release persists) and whether longer DCA exposures restore bulk ATP were not assessed.
  5. Sample sizes and variability: group n for some measures is modest (n=9–13), with relatively large SEs for extracellular ATP — increases uncertainty around effect sizes and requires independent replication.

What the data justify (conservative claims) vs overreach

• Justified: in rabbit RBCs in vitro, high extracellular lactate blocks the acute low-PO2–triggered increase in extracellular ATP; DCA restores that ATP release in the same system (Rozier key finding).
• Not proven: that lactate is the sole cause of impaired vascular regulation in sepsis/malaria patients — clinical disease includes many confounders (parasite adhesion, inflammation, anemia, endothelial dysfunction); DCA's lack of mortality benefit in some trials suggests this mechanism is only a part of the pathophysiology (Rozier clinical caution).

Confidence & what would change the conclusion

Moderate confidence that lactate can block hypoxia-triggered ATP release in this model (direct measured effect with rescue by DCA). Confidence that this mechanism plays a large role in human sepsis/malaria is low without further cross-species and in vivo corroboration. Evidence that would overturn or weaken the conclusion:

• Replication in human RBCs showing no inhibition at clinically relevant lactate concentrations.
• Demonstration that lactate's effect is indirect (via contaminating factors or assay interference) rather than directly impairing RBC ATP handling.
• Identification that DCA acts via an off-target effect on ATP detection or extracellular ATP degradation rather than restoring RBC releasable ATP production.

Suggested follow-up experiments (practical, falsifiable)

1. Human RBC dose–response: incubate human RBCs with 0, 2, 5, 10, 20 mmol·L⁻¹ lactate for 1 h, measure extracellular ATP release on low PO2, intracellular ATP, and cell viability; outcome: define clinical-likelihood range where inhibition occurs (falsifiable if no inhibition at clinically observed lactate concentrations).
2. Membrane microdomain assay: measure activity and localization of glycolytic enzymes (PFK, GAPDH) at RBC membrane (band 3) before/after lactate ± DCA using biochemical fractionation and enzyme assays; outcome: show whether lactate selectively suppresses membrane-associated glycolysis relevant to release pool.
3. Block G i or ATP channels: apply pertussis toxin or known ATP-channel blockers to test whether lactate's effect is upstream (sensing) or downstream (supply) — if lactate still blocks release when Gi is inhibited, that suggests supply-limited mechanism.
4. In vivo model: modestly elevating plasma lactate in an intact animal while measuring microvascular conductance and RBC ATP release in plasma/venous effluent to test translational relevance.

Related modern context

Recent reviews synthesize RBCs as active signaling cells releasing ATP and other mediators during exercise and stress, placing this paper in a broader framework that RBC-derived ATP contributes to microvascular control but is one among multiple erythrocyte 'exerkines' (reviewed 2025) (2025 erythrocyte exerkines review).